

CCDC12 RABBIT PAB

货号: S218439

产品全名: CCDC12 兔多抗

基因符号

UNIPROT ID: Q8WUD4 (Gene Accession - BC020830)

背景: CCDC12, also known as FLJ39430, FLJ40801 or MGC23918, is a 166 amino acid protein encoded by a gene mapping to human chromosome 3. Chromosome 3 is made up of about 214 million bases encoding over 1,100 genes. Notably, there is a chemokine receptor gene cluster and a variety of human cancer related loci on chromosome 3. Particular regions of the chromosome 3 short arm are deleted in many types of cancer cells. Key tumor suppressing genes on chromosome 3 encode apoptosis mediator RASSF1, cell migration regulator HYAL1 and angiogenesis suppressor SEMA3B. Marfan Syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth Disease are a few of the numerous genetic diseases associated with chromosome 3.

抗原: Full length fusion 蛋白

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-300; ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cell Biology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 218439 (CCDC12 Antibody) at a dilution of 1/60 (Nucleus).



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the fusion protein and then with 218439 (Anti-CCDC12 Antibody) at dilution 1/60.



The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using 218439 (Anti-CCDC12 Antibody) at a dilution of 1/60.



In comparison with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with fusion protein and then with D224435 (Anti-CCDC12 Antibody) at dilution 1/60.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
